Ciro Rinaldi, David Ross, Lynette Chee, Alessandra Iurlo, Chun Teh, Francesca Palandri, Maria Laura Fox, Jennifer O'Sullivan, Marco Brociner, Jen Salstrom, Xin Tong, Varsha Sundaresan, Leopold Sellner, Katsuhiro Togami, Claire Harrison. "Hematological and clinical improvements with elritercept (KER-050, TAK-226) at the recommended Phase 2 dose (RP2D) in patients with myelofibrosis (MF) receiving ruxolitinib: Updated results from the Phase 2 restore trial." Blood, 2025. doi:10.1182/blood-2025-909